LL-37 vs Oxytocin
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
LL-37
LL-37 is the only human cathelicidin — a host defense peptide produced by neutrophils, epithelial cells, and macrophages in response to infection and inflammation. It functions simultaneously as a broad-spectrum antimicrobial agent and an immune-modulatory signaling molecule. Research interest has expanded dramatically since COVID-19 studies linked low LL-37 levels to severe outcomes, and gut health research identified it as a key regulator of intestinal barrier integrity.
Full profileOxytocin
Endogenous 9-amino acid neuropeptide produced in the hypothalamus with roles in social bonding, trust, and childbirth. Research applications span wound healing, anti-inflammatory effects, sexual function, anxiety reduction, and autonomic nervous system regulation. Intranasal administration crosses the blood-brain barrier and is the primary research route for behavioral and neurological applications.
Full profile| LL-37 | Oxytocin | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Cathelicidin LL-37, hCAP-18 C-terminal fragment, CRAMP (murine equivalent) | OT, Pitocin, Syntocinon, trust hormone, bonding peptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | 100mcg–500mcg mcg, Daily or 3–5x weekly | 10–20IU–100–160IU IU, Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols |
| Administration | Subcutaneous injection, Intranasal (for respiratory applications), Topical (wound care) | Intranasal spray, Subcutaneous injection, Intravenous (clinical) |
| Key side effects | Injection site redness and irritation (common — pro-inflammatory at injection site), Transient flu-like symptoms (immune activation), Local induration, High doses may be cytotoxic — dose-response curve is non-linear | Nausea, Headache, Transient hypotension, Hyponatremia (high IV doses — water retention effect) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: LL-37 — Subcutaneous injection, Intranasal (for respiratory applications), Topical (wound care); Oxytocin — Intranasal spray, Subcutaneous injection, Intravenous (clinical).
- Dosing units differ: LL-37 is dosed in mcg, Oxytocin in IU — they operate at different scales.
- Frequency: LL-37 is typically Daily or 3–5x weekly; Oxytocin is Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols.
- Research depth: this profile cites 3 sources for LL-37 vs 2 for Oxytocin.
How each works
LL-37
LL-37 exerts antimicrobial activity by disrupting bacterial membranes via electrostatic interaction with negatively charged lipopolysaccharide — effective against gram-positive and gram-negative bacteria, fungi, and enveloped viruses including SARS-CoV-2 in vitro. Beyond direct antimicrobial action, LL-37 modulates innate immunity through TLR4 signaling, promotes wound healing via EGFR and FPRL1 receptor activation, and has demonstrated anti-biofilm activity against P. aeruginosa and S. aureus. Vitamin D is the primary driver of endogenous LL-37 production.
Oxytocin
Oxytocin binds oxytocin receptors (OTR) throughout the brain and periphery, producing prosocial, anxiolytic, and anti-inflammatory effects. The landmark 2005 Kosfeld et al. Nature study demonstrated that intranasal oxytocin increased trust in humans in economic game paradigms. Peripheral effects include acceleration of wound healing, modulation of inflammatory cytokines, and parasympathetic nervous system activation.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.